KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill targets tough cancers: early trial shows promise
Disease control CompletedThis study tested an oral drug called GFH925 in 334 people with advanced solid tumors that have a specific KRAS G12C mutation. The trial aimed to find the safest dose and check if the drug can shrink tumors in cancers like lung and colorectal cancer. Results will help decide if l…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC